A Phase 1 interventional study of AND017 single dose and AND017 multiple dose in Healthy Volunteers, sponsored by Kind Pharmaceuticals LLC. Completed at 1 site in Australia. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-11.
Sponsored by Kind Pharmaceuticals LLC · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase I, randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate safety, tolerability, PKs and PDs of AND017 following oral single and multiple dose administration.
Kind Pharmaceuticals LLC is the lead sponsor of 11 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be administrated with single dose of AND017 capsule from 1 mg to 50 mg during Part A.
Drug: AND017 single dose
Subjects will be administrated with repeated dose of AND017 from 4 mg to 30 mg for 10 consecutive days during Part B.
Drug: AND017 multiple dose
Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
Drug: Placebo
AND017 administrated as oral single-dose on Day 1 in Part A
AND017 administrated once daily from Day 1 to Day 10 in Part B
Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
Safety evaluations
Incidents of AE and abnormal laboratory tests
Time frame: 17 Days
Plasma Cmax of AND017
The plasma Cmax of AND017 by single dose administration
Time frame: 1 day
Plasma Tmax of AND017
The plasma Tmax of AND017 after single dose administration on D1 and multiple doses for 10 consecutive days on D10
Time frame: 1 day and 10 days
Plasma t1/2 of AND017
The plasma T1/2 of AND017 after single dose administration on D1 and multiple doses for 10 consecutive days on D10
Time frame: 1 day and 10 days
Plasma AUC of AND017
The plasma AUCs of AND017 after single dose administration on D1 and multiple doses for 10 consecutive days on D10
Time frame: 1 day and 10 days
Plasma CL/F of AND017
The plasma CL/F of AND017 after single dose administration
Time frame: 1 day
Plasma Vz/F of AND017
The plasma Vz/F of AND017 after single dose administration
Time frame: 1 day
Plasma MRT of AND017
The plasma MRT of AND017 after single dose administration
Time frame: 1 day
Plasma λz of AND017
The plasma λz of AND017 after single dose administration
Time frame: 1 day
Plasma %AUCex of AND017
The plasma %AUCex of AND017 after single dose administration
Time frame: 1 day
Plasma Css,min of AND017
The plasma Css,min of AND017 by multiple administration for 10 consecutive days
Time frame: 10 days
Plasma Css,max of AND017
The plasma Css,max of AND017 by multiple administration for 10 consecutive days
Time frame: 10 days
Plasma Css,avg of AND017
The plasma Css,avg of AND017 by multiple administration for 10 consecutive days
Time frame: 10 days
Plasma CLss/F of AND017
The plasma CLss/F of AND017 by multiple administration for 10 consecutive days
Time frame: 10 days
Plasma Vss/F of AND017
The plasma Vss/F of AND017 by multiple administration for 10 consecutive days
Time frame: 10 days
Plasma Rac(AUC) of AND017
The plasma Rac(AUC) of AND017 by multiple administration for 10 consecutive days
Time frame: 10 days
Plasma DF of AND017
The plasma DF of AND017 by multiple administration for 10 consecutive days
Time frame: 10 days
PD parameters
Change from baseline levels of EPO
Time frame: 17 days
PD parameters
Change from baseline levels of HB
Time frame: 17 days
PD parameters
Change from baseline levels of RET
Time frame: 17 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2018 to primary completion in Feb 2019, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AND017
Kind Pharmaceuticals LLC